Identification of Fucosylated Fetuin-A As a Potential Biomarker for Cholangiocarcinoma

Overview

Journal Proteomics Clin Appl

Specialty Biochemistry

Date 2017 Jun 1

PMID 28561948

Citations 14

Authors

Lucy Betesh

Mary Ann Comunale

Mengjun Wang

Hongyan Liang

Julie Hafner

Aykan Karabudak

Nasra H Giama

Catherine D Moser

Eiji Miyoshi

Lewis R Roberts

Timothy M Block

Anand Mehta

Affiliations

Soon will be listed here.

Abstract

Purpose: Cholangiocarcinoma (CCA) is a malignancy of the bile ducts. The purpose of this discovery study was to identify effective serum markers for surveillance of cholangiocarcinoma.

Experimental Design: Using a glycomic method, patients with CCA were determined to have increased levels of alpha-1,3 and alpha-1,6 linked fucosylated glycan. Proteomic analysis of the serum fucosylated proteome identified proteins such as alpha-2-macroglobulin, kininogen, hemopexin, fetuin-A, alpha-1 anti-trypsin, and ceruloplasmin as being hyperfucosylated in HCC. The levels of these glycoproteins in 109 patients with CCA, primary sclerosing cholangitis (PSC), and control patients were compared to the performance of CA-19-9, the current "gold standard" assay for cholangiocarcinoma.

Results: Fucosylated Fetuin-A (fc-Fetuin-A) had the best ability to differentiate CCA from PSC, with an AUROC of 0.812 or 0.8665 at differentiating CCA from those with PSC or other liver disease. CA-19-9 had poor ability to differentiate PSC from cholangiocarcinoma (AUROC of 0.625).

Conclusion And Clinical Relevance: Using glycomic and proteomic methods we identified a set of proteins that contain altered glycan in the sera of those with CCA. One of these proteins, fucosylated Fetuin-A may have value in the surveillance of people at risk for the development of cholangiocarcinoma.

Citing Articles

Spatial omics-based machine learning algorithms for the early detection of hepatocellular carcinoma.

Wang M, Grauzam S, Bayram M, Dressman J, DelaCourt A, Blaschke C Commun Med (Lond). 2024; 4(1):258.

PMID: 39627514 PMC: 11614901. DOI: 10.1038/s43856-024-00677-7.

Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis.

El-Serag H, Kanwal F, Ning J, Powell H, Khaderi S, Singal A Gut. 2024; .

PMID: 38365278 PMC: 11327383. DOI: 10.1136/gutjnl-2024-332034.

Combined analysis of secreted proteins and glycosylation identifies prognostic features in cholangiocarcinoma.

Park D, Xu G, Park S, Haigh N, Phoomak C, Wongkham S J Cell Physiol. 2023; 239(3):e31147.

PMID: 37921263 PMC: 10939962. DOI: 10.1002/jcp.31147.

Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma: From Pathogenesis to Diagnostic and Surveillance Strategies.

Catanzaro E, Gringeri E, Burra P, Gambato M Cancers (Basel). 2023; 15(20).

PMID: 37894314 PMC: 10604939. DOI: 10.3390/cancers15204947.

Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma.

Ochoa-Rios S, Blaschke C, Wang M, Peterson K, DelaCourt A, Grauzam S Cancer Res Commun. 2023; 3(3):383-394.

PMID: 36890858 PMC: 9987250. DOI: 10.1158/2767-9764.CRC-22-0422.

References

Aoyagi Y, Isokawa O, Suda T, Watanabe M, Suzuki Y, Asakura H . The fucosylation index of alpha-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma. Cancer. 1998; 83(10):2076-82. View

Comunale M, Rodemich-Betesh L, Hafner J, Wang M, Norton P, Di Bisceglie A . Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer patients: implications for a biomarker of hepatocellular carcinoma. PLoS One. 2010; 5(8):e12419. PMC: 2928295. DOI: 10.1371/journal.pone.0012419. View

Mehta A, Long R, Comunale M, Wang M, Rodemich L, Krakover J . Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol. 2007; 82(3):1259-70. PMC: 2224448. DOI: 10.1128/JVI.01600-07. View

Rudd P, Dwek R . Rapid, sensitive sequencing of oligosaccharides from glycoproteins. Curr Opin Biotechnol. 1997; 8(4):488-97. DOI: 10.1016/s0958-1669(97)80073-0. View

Wang M, Long R, Comunale M, Junaidi O, Marrero J, Di Bisceglie A . Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2009; 18(6):1914-21. PMC: 4413450. DOI: 10.1158/1055-9965.EPI-08-0980. View

Ramage J, Donaghy A, Farrant J, Iorns R, Williams R . Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology. 1995; 108(3):865-9. DOI: 10.1016/0016-5085(95)90462-x. View

Patel A, Harnois D, Klee G, Larusso N, Gores G . The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000; 95(1):204-7. DOI: 10.1111/j.1572-0241.2000.01685.x. View

Saldova R, Reuben J, Abd Hamid U, Rudd P, Cristofanilli M . Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts. Ann Oncol. 2010; 22(5):1113-1119. DOI: 10.1093/annonc/mdq570. View

Guile G, Rudd P, Wing D, Prime S, Dwek R . A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal Biochem. 1996; 240(2):210-26. DOI: 10.1006/abio.1996.0351. View

10.

Block T, Comunale M, Lowman M, Steel L, Romano P, Fimmel C . Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A. 2005; 102(3):779-84. PMC: 545516. DOI: 10.1073/pnas.0408928102. View

11.

Rudd P, Colominas C, Royle L, Murphy N, Hart E, Merry A . A high-performance liquid chromatography based strategy for rapid, sensitive sequencing of N-linked oligosaccharide modifications to proteins in sodium dodecyl sulphate polyacrylamide electrophoresis gel bands. Proteomics. 2001; 1(2):285-94. DOI: 10.1002/1615-9861(200102)1:2<285::AID-PROT285>3.0.CO;2-G. View

12.

Rudd P, Guile G, Kuster B, Harvey D, Opdenakker G, Dwek R . Oligosaccharide sequencing technology. Nature. 1997; 388(6638):205-7. DOI: 10.1038/40677. View

13.

Saldova R, Wormald M, Dwek R, Rudd P . Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis Markers. 2009; 25(4-5):219-32. PMC: 3827796. DOI: 10.1155/2008/601583. View

14.

Saldova R, Royle L, Radcliffe C, Abd Hamid U, Evans R, Arnold J . Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology. 2007; 17(12):1344-56. DOI: 10.1093/glycob/cwm100. View

15.

Noda K, Miyoshi E, Gu J, Gao C, Nakahara S, Kitada T . Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines. Cancer Res. 2003; 63(19):6282-9. View

16.

Comunale M, Lowman M, Long R, Krakover J, Philip R, Seeholzer S . Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res. 2006; 5(2):308-15. DOI: 10.1021/pr050328x. View

17.

Naitoh A, Aoyagi Y, Asakura H . Highly enhanced fucosylation of serum glycoproteins in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 1999; 14(5):436-45. DOI: 10.1046/j.1440-1746.1999.01882.x. View

18.

Morota K, Nakagawa M, Sekiya R, Hemken P, Sokoll L, Elliott D . A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Clin Chem Lab Med. 2011; 49(4):711-8. DOI: 10.1515/CCLM.2011.097. View

19.

Nichols J, Gores G, Larusso N, Wiesner R, Nagorney D, RITTS Jr R . Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc. 1993; 68(9):874-9. DOI: 10.1016/s0025-6196(12)60696-x. View

20.

Arnold J, Saldova R, Galligan M, Murphy T, Mimura-Kimura Y, Telford J . Novel glycan biomarkers for the detection of lung cancer. J Proteome Res. 2011; 10(4):1755-64. DOI: 10.1021/pr101034t. View